Immunogens and Immunization Schedules. 10-to 12-week old female BALB/cAnN mice were injected with purified myelomaproteins 315 or 460, which were isolated by subjection of the proteins to mild reduction and alkylation (in this work with iodoacetic acid) (2, 3). Proteins 315 and 460 purified in this manner (820w,, = 6.5) have about eight carboxymethyl groups per molecule (150,000 daltons), one on the C-terminal or penultimate cysteine of the light chain and 3-4 on the heavy chain (4). Both purified proteins had intact ligandbinding sites, as shown by specific quenching of their tryptoAbbreviation: TD5o, number of cells required to produce tumors in 50% of control (untreated) animals; Dnp, 2,4-dinitrophenyl.
Antibodies made by BALB/c mice to myeloma proteins from mouse plasmacytomas of BALB/c origin were previously found to be specific for the individually distinctive ("idiotypic") determinants that seem to be localized in the respective ligand-binding sites of these proteins (1) . The tumor cells that produce a myeloma protein should have altered growth properties (enhancement or suppression) in mice that produce such an immune response if the protein were localized in the cell membrane. In this study, we show that BALB/c mice immunized with myeloma proteins 315 or 460 can specifically suppress the growth of the corresponding tumor, MOPC-315 or MOPC-460. Selection by the host immune response was probably responsible for the additional finding that variant MOPC-315 tumors that produce only the light chain of protein 315, grew in several of the mice immunized with whole molecules of protein 315 (light plus heavy chains).
MATERIALS AND METHODS
Immunogens and Immunization Schedules. 10-to 12-week old female BALB/cAnN mice were injected with purified myelomaproteins 315 or 460, which were isolated by subjection of the proteins to mild reduction and alkylation (in this work with iodoacetic acid) (2, 3) . Proteins 315 and 460 purified in this manner (820w,, = 6.5) have about eight carboxymethyl groups per molecule (150,000 daltons), one on the C-terminal or penultimate cysteine of the light chain and 3-4 on the heavy chain (4) . Both purified proteins had intact ligandbinding sites, as shown by specific quenching of their tryptoAbbreviation: TD5o, number of cells required to produce tumors in 50% of control (untreated) animals; Dnp, 2,4-dinitrophenyl. * 
Tumor immunity
Immunized mice were challenged with 5,000-10,000 MOPC-315 cells or with 50,000-100,000 MOPC-460 cells. These quantities were two to six times the numbers required to produce tumors in 50% of control mice (TD50) (Fig. 1 Immunity to Myeloma Tumors of those mice tested with 10,000 cells (Fig. 2, Table 2 ). The MOPC-315 tumors that grew in mice immunized with protein 315 appeared later than in controls, and most (12/18) were variants that no longer produced protein 315 (Table 2) .
After two transfers in nonimmunized hosts, two of the MOPC-315 variants were found to produce protein 315, as indicated by elevated serum concentrations of IgA and precipitin reactions of serum with Dnp-proteins. The remaining variants (10/12) continued not to produce protein 315 through 9 transfers over 6 months in unimmunized mice. Instead, these stable variants produced the light chain of protein 315: urine samples from mice carrying the stable variants and authentic light chain isolated from purified protein 315 gave reactions of identity in double diffusion gel precipitin tests with a rabbit antiserum specific for the light chain (see Methods). (This observation, by Dr. Kristian Hannest'd, will be described in detail in a later report.) Urine from mice carrying the standard ("wild-type") MOPC-315 did not form a precipitate with this rabbit antiserum.
As in the 315 system, BALB/cAnN mice immunized with protein 460 became resistant to MOPC-460, but the effect was more difficult to jiscern. In one experiment resistance was suggested only by delayed onset of tumors and prolonged survival of tumor-bearing mice (not shown), rather than by a decreased incidence of tumors ( Fig. 2C and D) . However, in a second experiment, in which the immunization schedule (D) was prolonged, a decreased incidence of tumors was observed ( Table 2 , Fig. 2E ). Moreover, MOPC-460 tumors appeared and then regressed completely in two mice immunized with protein 460, whereas tumor regression was not observed in any of the control BALB/cAnN mice. In one mouse immunized with protein 460 a massive (fatal) tumor developed but the serum contained no detectable protein 460. However, when this tumor was transferred to a nonimmunized host an IgA myeloma protein with anti-Dnp activity (probably protein 460) was detectable in serum after about 3 weeks. 
DISCUSSION
These experiments show that myeloma proteins 315 and 460 can function as tumor-specific transplantation antigens: each protein can induce an immune response that leads to specific rejection of the corresponding tumor. As was shown (1), and confirmed here, antibodies made by BALB/c mice to proteins 315 and 460 are specific for their respective idiotypic determinants. The resistance to myeloma cells induced by tlese proteins is probably also specific for idiotypic determinants, because mice rendered resistant to MOPC-315 (1972) tutes of Health (GM-00897).
